Test Code Billings Clinic 9168 Mayo: LPMGF Lymphocyte Proliferation to Mitogens, Blood
Reporting Name
Lymphocyte Proliferation, MitogensPerforming Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Assessing T-cell function in patients on immunosuppressive therapy, including solid-organ transplant patients
Evaluating patients suspected of having impairment in cellular immunity
Evaluation of T-cell function in patients with primary immunodeficiencies, either cellular (DiGeorge syndrome, T-negative severe combined immunodeficiency: SCID, etc) or combined T- and B-cell immunodeficiencies (T- and B-negative SCID, Wiskott-Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency, among others) where T-cell function may be impaired
Evaluation of T-cell function in patients with secondary immunodeficiency, either disease related or iatrogenic
Evaluation of recovery of T-cell function and competence following bone marrow transplantation or hematopoietic stem cell transplantation
Method Name
Flow Cytometry
Shipping Instructions
Testing performed Monday through Friday. Specimens not received by 4 p.m. Central time on Friday may be canceled.
Specimens arriving on the weekend and observed holidays may be canceled.
Collect and package specimen as close to shipping time as possible. Ship specimen overnight in an Ambient Shipping Box-Critical Specimens Only (T668) following the instructions in the box. It is recommended that specimens arrive within 24 hours of collection.
Necessary Information
1. Date and time of collection are required.
2. The ordering healthcare professional's name and phone number are required.
Specimen Required
Supplies: Ambient Shipping Box-Critical Specimens Only (T668)
Container/Tube: Green top (sodium heparin)
Specimen Volume: 20 mL
See tables for information on recommended volume based on absolute lymphocyte count
Pediatric Volume:
<3 months: 1 mL
3-24 months: 3 mL
25 months-18 years: 5 mL
Collection Instructions: Send whole blood specimen in original tube. Do not aliquot.
Additional Information: For serial monitoring, it is recommended that specimen collection be performed at the same time of day.
Table. Blood Volume Recommendations Based on Absolute Lymphocyte Count (ALC)
Mitogen only |
|||
ALC x 10(9)/L |
Blood volume for minimum phytohemagglutinin (PHA) only |
Blood volume for minimum PHA and pokeweed mitogen (PWM) |
Blood volume for full assay |
<0.5 |
>6.5 mL |
>8.5 mL |
>22 mL |
0.5-1.0 |
6.5 mL |
8.5 mL |
22 mL |
1.1-1.5 |
3.0 mL |
4.0 mL |
10 mL |
1.6-2.0 |
2.0 mL |
2.5 mL |
7 mL |
2.1-3.0 |
1.5 mL |
2.0 mL |
6 mL |
3.1-4.0 |
1.0 mL |
1.5 mL |
4 mL |
4.1-5.0 |
0.8 mL |
1.0 mL |
3 mL |
>5.0 |
0.5 mL |
0.8 mL |
2 mL |
Mitogen and antigen |
||
ALC x 10(9)/L |
Blood volume for minimum of each assay |
Blood volume for full assay |
<0.5 |
>28 mL |
>60 mL |
0.5-1.0 |
28 mL |
60 mL |
1.1-1.5 |
12 mL |
30 mL |
1.6-2.0 |
8.5 mL |
20 mL |
2.1-3.0 |
6.5 mL |
15 mL |
3.1-4.0 |
4.5 mL |
10 mL |
4.1-5.0 |
3.5 mL |
8 mL |
>5.0 |
2.5 mL |
6 mL |
Specimen Type
WB Sodium HeparinSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
WB Sodium Heparin | Ambient | 48 hours | GREEN TOP/HEP |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Reference Values
Viability of lymphocytes at day 0: ≥75.0%
Maximum proliferation of phytohemagglutinin as % CD45: ≥49.9%
Maximum proliferation of phytohemagglutinin as % CD3: ≥58.5%
Maximum proliferation of pokeweed mitogen as % CD45: ≥4.5%
Maximum proliferation of pokeweed mitogen as % CD3: ≥3.5%
Maximum proliferation of pokeweed mitogen as % CD19: ≥3.9%
Interpretation
Abnormal mitogen stimulation test results are indicative of impaired T-cell function if T-cell counts are normal or only modestly decreased. If there is profound T-cell lymphopenia, there could be a dilution effect with under-representation of T cells within the peripheral blood mononuclear cell population that could result in lower T-cell proliferative responses. However, this is not a significant concern in the flow cytometry assay since acquisition of additional cellular events during analysis can compensate for artificial reduction in proliferation due to lower T-cell counts.
There is no absolute correlation between T-cell proliferation in vitro and a clinically significant immunodeficiency, whether primary or secondary, since T-cell proliferation in response to activation is necessary, but not sufficient, for an effective immune response. Therefore, the proliferative response to mitogens can be regarded as a more specific, but less sensitive, test for the diagnosis of infection susceptibility.
No single laboratory test can identify or define impaired cellular immunity on its own.
Controls in this laboratory and most clinical laboratories are healthy adults. Since this test is used for screening and evaluating cellular immune dysfunction in infants and children, it is reasonable to question the comparability of proliferative responses between healthy infants, children, and adults. One study has reported that the highest mitogen responses are seen in newborn infants with subsequent decline to 6 months of age and a continuing decline through adolescence to half the neonatal response.(9) In an in-house evaluation of 43 pediatric specimens (of all ages) with adult normal controls, only 21% and 14% were below the tenth percentile of the adult reference range for pokeweed and phytohemagglutinin, respectively. A comment will be provided in the report documenting the comparison of pediatric results with an adult reference range and correlation with clinical context for appropriate interpretation.
Without obtaining formal pediatric reference values, it remains a possibility that the response in infants and children can be underestimated. However, the practical challenges of generating a pediatric range for this assay necessitate comparison of pediatric data with adult reference values or controls.
Lymphocyte proliferation responses to mitogens and antigens are significantly affected by time elapsed since blood collection. Results have been shown to be variable for specimens assessed between 24- and 48-hours post blood collection; therefore, lymphocyte proliferation results must be interpreted with due caution and results should be correlated with clinical context.
Day(s) Performed
Monday through Friday
Report Available
8 to 11 daysTest Classification
This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86353
86353 (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
LPMGF | Lymphocyte Proliferation, Mitogens | 69018-0 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
32317 | Interpretation | 69052-9 |
32318 | Viab of Lymphs at Day 0 | 33193-4 |
32321 | Max Prolif of PWM as % CD45 | 69019-8 |
32322 | Max Prolif of PWM as % CD3 | 69020-6 |
32323 | Max Prolif of PWM as % CD19 | 69037-0 |
32319 | Max Prolif of PHA as % CD45 | 69038-8 |
32320 | Max Prolif of PHA as % CD3 | 57741-1 |
32324 | Mitogen Comment | 48767-8 |
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
MGSTM | Additional Flow Stimulant, LPMGF | No, (Bill Only) | No |
Testing Algorithm
To ensure the most reliable results, if insufficient peripheral blood mononuclear cells are isolated from the patient's sample due to low white blood cell counts or specimen volume received, selected dilutions or stimulants may not be tested at the discretion of the laboratory.
Testing with one stimulant will always be performed. When adequate specimen is available for both stimulants to be tested, the second stimulant will be evaluated at an additional charge.